Another Covid-19 vaccine linked to blood clots among recipients

As of April 12, more than 6.8 million doses of the J&J vaccine had been administered in the United States. [File, Standard]

U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson’s COVID-19 vaccine after six recipients developed a rare disorder involving blood clots, in a fresh setback to global efforts to tackle the pandemic.

The move comes a week after European regulators said they had found a possible link between AstraZeneca’s COVID-19 vaccine and a rare blood clotting problem that had led to a small number of deaths.